<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William Hopkins, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lewis J Rubin, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jess Mandel, MD, MACP, ATSF, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pulmonary hypertension (PH) is classified into five groups based upon etiology. Patients in the first group are considered to have pulmonary arterial hypertension (PAH), whereas patients in the remaining four groups are considered to have PH  (<a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef120362" href="/z/d/graphic/120362.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef120363" href="/z/d/graphic/120363.html" rel="external">table 3</a>). In this topic, we discuss PAH-specific therapy, while general measures for treating PAH, as well as pathogenesis, diagnosis, classification, and prognosis of PAH, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)"</a> and  <a class="medical medical_review" href="/z/d/html/8247.html" rel="external">"The epidemiology and pathogenesis of pulmonary arterial hypertension (Group 1)"</a> and  <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"</a>.)</p><p>Our approach for the most part is in keeping with several guideline groups [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H16"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>PAH-specific therapy (also known as PAH-targeted or PAH-directed therapy) is directed at the PAH itself rather than the underlying cause of the PAH. PAH-specific agents include prostacyclin pathway agonists, endothelin receptor antagonists, nitric oxide-cyclic guanosine monophosphate enhancers, or, rarely, select calcium channel blockers  (<a class="graphic graphic_table graphicRef50798" href="/z/d/graphic/50798.html" rel="external">table 4</a>).</p><p class="headingAnchor" id="H3592956055"><span class="h1">PRETREATMENT EVALUATION</span><span class="headingEndMark"> — </span>Patients with PAH should be referred to a specialized center for evaluation and management since the administration of PAH-specific therapy can be harmful. Before PAH-specific therapy is administered:</p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of PAH, and any potential associated etiology, should be in place, since PAH-specific therapy has not been found to be beneficial in most other forms of PH and may, in fact, be harmful. (See  <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When indicated, vasoreactivity testing should be performed. (See <a class="local">'Vasoreactive patients'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The baseline risk of disease progression and death should be assessed. (See <a class="local">'Vasoreactivity testing (select patients)'</a> below.)</p><p></p><p class="headingAnchor" id="H352845626"><span class="h2">Vasoreactivity testing (select patients)</span><span class="headingEndMark"> — </span>Select patients with PAH (ie, group 1 PH)  (<a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">table 1</a>) should undergo acute vasoreactivity testing (AVT) to identify the small subset of PAH patients (10 to 20 percent) who may respond to calcium channel blocker (CCB) therapy. This includes patients with idiopathic PAH (IPAH), heritable PAH, and drug/toxin-induced PAH (ie, patients who are most likely to be vasoreactive).</p><p>Patients with associated forms of PAH are rarely vasoreactive, and, as such, vasoreactivity testing is <strong>not</strong> indicated [<a href="#rid2">2</a>]. This includes patients with PAH due to connective tissue disease, congenital heart disease, human immunodeficiency virus (HIV), portal hypertension, and schistosomiasis and patients with suspected pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis.</p><p>Contraindications to AVT include low systemic blood pressure (eg, systolic BP &lt;90 mmHg), low cardiac index (cardiac index &lt;2 L/min/m<sup>2</sup>), or presence of severe (functional class IV) symptoms  (<a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">table 5</a>) since hypotension and occasionally cardiovascular collapse can occur with the administration of the vasodilator. Caution should also be exercised if it is suspected that patients have a component of group 2 PH (ie, cardiovascular causes of PH  (<a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">table 1</a>)).</p><p>Patients with a positive vasoreactivity test are candidates for a trial of CCB therapy (see <a class="local">'Calcium channel blockers (trial)'</a> below). In contrast, CCB therapy should be avoided in patients with a negative test since CCBs can have serious adverse effects, including systemic hypotension and death, in this population. Choice of therapy in nonvasoreactive patients is discussed below. (See <a class="local">'Nonvasoreactive patients'</a> below.)</p><p>AVT involves the administration of a short-acting vasodilator followed by measurement of the hemodynamic response using a right heart catheter. Agents commonly used for vasoreactivity testing include <a class="drug drug_general" data-topicid="9447" href="/z/d/drug information/9447.html" rel="external">inhaled nitric oxide</a>, <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a>, <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a>, and inhaled <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">iloprost</a>:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9447" href="/z/d/drug information/9447.html" rel="external">Inhaled nitric oxide</a> is the most common agent used and is administered at 10 to 20 ppm. It is selective for the pulmonary vasculature with minimal systemic effects and is therefore better tolerated than other agents [<a href="#rid3">3-7</a>]. Procedure and efficacy details are provided separately. (See  <a class="medical medical_review" href="/z/d/html/8264.html" rel="external">"Inhaled nitric oxide in adults: Biology and indications for use"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">Epoprostenol</a> is infused at a starting rate of 1 to 2 ng/kg per minute and increased by 2 ng/kg per minute every 5 to 10 minutes until a clinically significant fall in blood pressure, an increase in heart rate, or adverse symptoms (eg, nausea, vomiting, headache) develop  (<a class="graphic graphic_table graphicRef50798" href="/z/d/graphic/50798.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">Adenosine</a> is administered intravenously in doses of 50 mcg/kg per minute and increased every two minutes until uncomfortable symptoms develop or a maximal dose of 200 to 350 mcg/kg per minute is reached.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inhaled <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">iloprost</a>, while in theory can be used as an AVT agent, is not frequently administered for this purpose.</p><p></p><p>The test is considered positive if mean pulmonary artery pressure decreases at least 10 mmHg and to a value less than or equal to 40 mmHg, with an increased or unchanged cardiac output, and a minimally reduced or unchanged systemic blood pressure. "Borderline" results are considered as nonreactive.</p><p class="headingAnchor" id="H535634337"><span class="h2">Baseline risk assessment</span></p><p class="headingAnchor" id="H1081101952"><span class="h3">Our approach</span><span class="headingEndMark"> — </span>In patients with PAH, the baseline risk of disease progression and death should be assessed prior to the initiation of PAH-specific therapy. Risk stratification determines the initial regimen chosen and is also used to determine disease progression and response to therapy  (<a class="graphic graphic_algorithm graphicRef71168" href="/z/d/graphic/71168.html" rel="external">algorithm 1</a>). Without an agreed-upon optimal approach, our strategy is to choose an agent primarily based upon AVT and World Health Organization (WHO) functional class  (<a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">table 5</a>). This approach is practical since WHO functional class is a major determinant of outcome; consequently, regulatory approvals have been traditionally based upon WHO functional class. We subsequently individualize that therapy according to additional factors. These include established factors known to increase the risk of disease progression and death (eg, symptoms, evidence of right heart failure, right heart catheter hemodynamics)  (<a class="graphic graphic_table graphicRef123025" href="/z/d/graphic/123025.html" rel="external">table 6</a>), as well as patient preferences, approval status of the chosen drug, cost, route of administration, side effect profile, presence of comorbidities, and potential interaction with other drugs  (<a class="graphic graphic_table graphicRef123026" href="/z/d/graphic/123026.html" rel="external">table 7</a>). Specific drug interactions and management suggestions may be determined by using the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate.</p><p class="headingAnchor" id="H2820057861"><span class="h3">High- versus low-/intermediate-risk multiparameter risk assessment models</span><span class="headingEndMark"> — </span>Guidelines put forth by several societies suggest allocation of PAH-specific therapy based upon high-risk and low- or intermediate-risk categories [<a href="#rid1">1</a>]. In essence, patients assigned to the low- or intermediate-risk category should receive combination oral therapy similar to that described for WHO class II/III (with similar exceptions for alternate combination oral strategies and single-agent therapy) (see <a class="local">'WHO functional class II and III or low/intermediate risk (combination oral therapy)'</a> below) while high-risk patients should be placed on combination therapy that contains a parenteral prostanoid. (See <a class="local">'WHO functional class IV or high risk (parenteral prostanoid-containing combination regimen)'</a> below.)</p><p>Several groups have proposed other models for risk stratification. However, all of the proposed models have limitations and are not routinely or consistently used. These include the United States Registry to Evaluate Early and Long-term PAH disease management (REVEAL), the Swedish PAH Registry (SPAHR), The Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA), the French Pulmonary Hypertension Network (FPHN), the European Cardiology Society/European Respiratory Society (ECS/ERS) guidelines group, and the World Symposium of Pulmonary Hypertension  (<a class="graphic graphic_figure graphicRef85543" href="/z/d/graphic/85543.html" rel="external">figure 1</a> and <a class="graphic graphic_table graphicRef123025" href="/z/d/graphic/123025.html" rel="external">table 6</a> and <a class="graphic graphic_algorithm graphicRef129504" href="/z/d/graphic/129504.html" rel="external">algorithm 2</a>) [<a href="#rid1">1,8</a>]. Most of these models predict survival and involve a multidimensional approach that includes elements of clinical, biochemical (eg, brain natriuretic peptide), functional (eg, exercise capacity, WHO functional class), and hemodynamic parameters (echocardiography and pulmonary arterial catheter) that have prognostic significance  (<a class="graphic graphic_table graphicRef123025" href="/z/d/graphic/123025.html" rel="external">table 6</a>). However, it must be noted that all regulatory approvals are based in part on WHO functional class and none of these multi-risk assessment models have been used as an outcome to assess treatment in any PAH trial. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>The one-year survival of patients with newly diagnosed group 1 PAH may be predicted using a risk score derived from the REVEAL registry data [<a href="#rid9">9-12</a>]. The risk score is the sum of points derived from clinical data including group 1 subgroup, demographics, and comorbidities; functional class, vital signs, six-minute walk distance (6MWD), and brain natriuretic peptide level; and echocardiogram, pulmonary function tests, and right heart catheterization findings  (<a class="graphic graphic_figure graphicRef85543" href="/z/d/graphic/85543.html" rel="external">figure 1</a>) (<a class="calc calc_professional" href="/z/d/html/94386.html" rel="external">calculator 1</a>). Data were prospectively collected from 504 patients with a mean 6MWD of 308 meters, 62 percent of whom were classified as WHO functional class III  (<a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">table 5</a>). One-year survival correlated with risk score: 1 to 7 (95 percent), 8 (92 percent), 9 (89 percent), 10 to 11 (72 percent), and ≥12 (66 percent). Although not agreed upon, a score of 1 or less is considered low risk, a score between 2 and 9 is considered moderate risk, and a score of 10 or greater is high risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prognosis was reported using data derived from the COMPERA database [<a href="#rid13">13</a>]. Patients were risk stratified using a model that incorporated WHO functional class, 6MWD, brain natriuretic peptide levels, right atrial pressure, cardiac index, and mixed venous oxygen saturation. Mortality rates in patients at one year after diagnosis was 3 percent for low-risk patients, 10 percent for intermediate-risk patients, and 21 percent for high-risk patients  (<a class="graphic graphic_table graphicRef115237" href="/z/d/graphic/115237.html" rel="external">table 8</a>). A four-stratum risk profile has also been reported using refined cutoff levels for the same parameters in the original model [<a href="#rid14">14</a>]. Survival rates one year after diagnosis were 100 percent for low-risk patients, 98 percent for intermediate-/low-risk patients, 91 percent for intermediate-/high-risk patients, and 78 percent for high-risk patients.</p><p></p><p class="headingAnchor" id="H3679826799"><span class="h1">VASOREACTIVE PATIENTS</span></p><p class="headingAnchor" id="H2926359970"><span class="h2">Calcium channel blockers (trial)</span><span class="headingEndMark"> — </span>For patients with PAH who are vasoreactive, we administer an initial trial of calcium channel blocker (CCB) therapy (eg, one to three months). This only applies to patients with World Health Organization (WHO) class I to III since patients with WHO functional class IV do not typically undergo acute vasoreactivity testing nor are they generally candidates for oral therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Approximately 10 to 20 percent of PAH patients who undergo testing demonstrate a positive vasoreactive response. Among patients who are vasoreactive, approximately one-half clinically respond to CCB therapy. Among those who clinically improve, the response is generally short-lived, eventually requiring the addition of another agent of a different class. Long-term response is defined as an improvement in WHO functional class that is sustained for at least one year while on CCB therapy only (ie, same or better than that achieved in the initial vasoreactivity test and usually to an mean pulmonary artery pressure &lt;30 mmHg with increased or normal cardiac output) [<a href="#rid15">15</a>]. Only a proportion of vasoreactive patients have a long-term response (approximately 5 percent) [<a href="#rid16">16-19</a>].</p><p></p><p class="bulletIndent1">The evidence suggesting that CCB therapy is beneficial in terms of survival is limited by the absence of randomized trials comparing CCB therapy to no therapy in vasoreactive patients only. Without such trials, it is uncertain whether vasoreactive patients who receive CCB therapy truly benefit from the therapy or are predisposed to a better outcome, with vasoreactivity potentially being a marker of a better prognosis. However, in our experience, vasoreactive patients who experience a sustained lowering of pulmonary artery pressure feel remarkably better while on CCB therapy. Improved survival was reported in an observational study of 64 patients with idiopathic PAH (IPAH) that reported that the five-year survival was greater among patients who received CCB therapy (primarily <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a>) compared with a control group of patients (comprised nonvasoreactive IPAH patients and historical controls) [<a href="#rid16">16</a>]. Another observational study of 557 patients with IPAH found that only 13 percent had a positive vasoreactivity test and only 54 percent of the vasoreactive patients with IPAH who received CCB therapy maintained functional improvement after one year [<a href="#rid19">19</a>]. Responders were more vasoreactive (ie, had a greater decrease of mean pulmonary arterial pressure during the vasoreactivity test) and had less severe disease at baseline.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Agent and dosing</strong> – CCB therapy can be initiated as an outpatient with either long-acting <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> (30 mg/day) or <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a> (120 mg/day), which is then increased to the maximal tolerated dose over days to weeks  (<a class="graphic graphic_table graphicRef50798" href="/z/d/graphic/50798.html" rel="external">table 4</a>). Short-acting nifedipine should <strong>not</strong> be used. Systemic blood pressure, heart rate, and oxygen saturation should be carefully monitored during titration. Sustained release preparations of both nifedipine and diltiazem are available. Their use minimizes the adverse effects of therapy, especially systemic hypotension. <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">Amlodipine</a>, a long-acting dihydropyridine, is a useful alternative for patients who are intolerant of the other CCB agents.</p><p></p><p class="bulletIndent1">Patients who respond to CCB therapy should be reassessed after three to six months of treatment with a similar approach to that described below (see <a class="local">'Follow-up'</a> below). A poor response to therapy necessitates evaluation for non-CCB PAH-specific medication; in such patients, CCB therapy is generally stopped once patients demonstrate the need for double or triple therapy. (See <a class="local">'Nonvasoreactive patients'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Adverse effects are common among patients with PAH who are administered CCBs. Many of the adverse effects are a result of the potent systemic vasodilatory properties of CCBs (eg, hypotension and peripheral edema) [<a href="#rid20">20,21</a>]. Paradoxically, while pulmonary vasodilation from CCB therapy may reduce hypoxic vasoconstriction, loss of hypoxic vasoconstriction can worsen ventilation-perfusion mismatch and hypoxemia [<a href="#rid22">22,23</a>]. CCBs may also be associated with deterioration of right ventricular function due to the negative inotropic effect of CCBs [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/z/d/html/3832.html" rel="external">"Major side effects and safety of calcium channel blockers"</a>.)</p><p></p><p class="headingAnchor" id="H3095650616"><span class="h1">NONVASOREACTIVE PATIENTS</span><span class="headingEndMark"> — </span>For patients with PAH who are typically nonvasoreactive (eg, connective tissue disease-PAH, human immune deficiency PAH) and have not undergone vasoreactive testing (see <a class="local">'Vasoreactivity testing (select patients)'</a> above) and for patients who are nonvasoreactive or are vasoreactive and have failed CCB therapy, we generally use the World Health Organization (WHO) functional classification for selection of a suitable agent(s). WHO functional class and additional factors that influence agent selection are provided above  (<a class="graphic graphic_table graphicRef123026" href="/z/d/graphic/123026.html" rel="external">table 7</a> and <a class="graphic graphic_table graphicRef123025" href="/z/d/graphic/123025.html" rel="external">table 6</a>) (see <a class="local">'Pretreatment evaluation'</a> above). An alternate selection process is also suggested above (see <a class="local">'High- versus low-/intermediate-risk multiparameter risk assessment models'</a> above). Agent selection described in this section assumes treatment-naïvety.</p><p>PAH-specific therapy consistently improves hemodynamic measures, WHO functional class, and six-minute walk distance (6MWD) [<a href="#rid25">25,26</a>] and likely improves survival. Best illustrating this is a meta-analysis of 21 randomized trials (3140 patients) that found that therapy with a prostanoid, an endothelin receptor antagonist, or a phosphodiesterase-5 inhibitor improves mortality compared with no therapy (1.5 versus 3.8 percent; risk reduction 0.57, 95% CI 0.35-0.92) [<a href="#rid25">25</a>]. However, the average duration of treatment in trials was only 14 weeks. In addition, the same survival benefits may not apply to all patient subgroups within group 1 PAH. For example, although survival from systemic sclerosis-associated PAH has improved in the era of PAH-directed therapy, it is worse than that for idiopathic PAH (IPAH) and the mortality remains high, particularly when PH is associated with coexistent interstitial lung disease. (See  <a class="medical medical_review" href="/z/d/html/7542.html" rel="external">"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults", section on 'Prognosis'</a> and  <a class="medical medical_review" href="/z/d/html/8256.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Treatment and prognosis", section on 'Pulmonary arterial hypertension-directed therapy'</a> and  <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H244328193"><span class="h2">WHO functional class I (monotherapy)</span><span class="headingEndMark"> — </span>Patients rarely present with functional class I (because they are typically asymptomatic) and, in fact, this class is more likely to reflect patients on therapy who originally presented with a higher functional class. However, there is a small proportion of high-risk patients that undergo screening echocardiography that may present with WHO functional class I (eg, patients with scleroderma, patients with congenital heart disease and patients with known heritable PAH mutations). In practice, while some patients in this category, may be monitored closely for disease progression to a functional level that warrants therapy (eg, class II), we generally start PAH-specific monotherapy, particularly when patients have "high-risk" features  (<a class="graphic graphic_table graphicRef123025" href="/z/d/graphic/123025.html" rel="external">table 6</a>) or when significant elevations in the pulmonary artery pressure (PAP) is observed (eg, systolic PAP &gt;50 mmHg and mean PAP &gt;35 mmHg). This approach is based upon the rationale that PAH is progressive if left untreated and that therapy should prevent/slow disease progression [<a href="#rid27">27</a>]. There is no preference or data that support selecting one class of agent, and selection is usually at the discretion of the prescribing PH-specialist. Any coexisting conditions that worsen PH should also be treated (eg, obstructive sleep apnea). Despite these indications for single-agent therapy, pragmatically, there has been a paradigm shift in treatment in this group that advocates for combination therapy earlier in the disease process to stave off progression; thus, the threshold to add in a second agent should be low as the disease progresses.</p><p class="headingAnchor" id="H244328206"><span class="h2">WHO functional class II and III or low/intermediate risk (combination oral therapy)</span><span class="headingEndMark"> — </span>For patients with functional class II and III PAH or have low- or intermediate-risk PH, who are drug-naïve, we initially administer dual combination therapy with an endothelin receptor antagonist (ERA) and an agent that targets the nitric oxide-cyclic guanosine monophosphate (cGMP) pathway, typically a phosphodiesterase 5 inhibitor (PDE5I). Occasionally, a third agent (eg, <a class="drug drug_general" data-topicid="106041" href="/z/d/drug information/106041.html" rel="external">selexipag</a>) may be administered if escalated therapy is required during follow-up. (See <a class="local">'Follow-up'</a> below.)</p><p class="headingAnchor" id="H572704310"><span class="h3">Combination oral therapy</span><span class="headingEndMark"> — </span>In patients with WHO functional class II and III or with low- or intermediate-risk PH, we and other experts prefer the combination of the ERA <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">ambrisentan</a> and the PDE5I <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a> because it has been shown in this population to result in a significant reduction in the rate of clinical failure compared with monotherapy with either drug alone (see <a class="local">'Tadalafil plus ambrisentan'</a> below). For those who have a contraindication to either agent, another oral agent in the same class can be substituted (provided that two agents from the same class are <strong>not</strong> combined [eg, PDE5Is and <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">riociguat</a>]  (<a class="graphic graphic_table graphicRef50798" href="/z/d/graphic/50798.html" rel="external">table 4</a>)). However, such combinations are less well proven and drug interactions can potentially limit the outcome. Combination therapy may be administered as two agents initiated together (initial combination therapy; preferred by the authors of this topic) or as "add-ons" (ie, one followed by another; sequential combination therapy [eg, two to three weeks apart]) [<a href="#rid28">28,29</a>]. Some combinations are available as a single oral tablet (eg, <a class="drug drug_general" data-topicid="134604" href="/z/d/drug information/134604.html" rel="external">macitentan-tadalafil</a> combination).</p><p>Some patients may require triple-agent combination therapy, but we do not recommend triple agent therapy as an initial strategy.</p><p class="headingAnchor" id="H1074389035"><span class="h4">Tadalafil plus ambrisentan</span><span class="headingEndMark"> — </span>One randomized trial (AMBITION) of 500 drug-naïve patients with group 1 PAH (mostly idiopathic and connective tissue disease [CTD]-related) who had class II or III symptoms compared the combination of 10 mg of <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">ambrisentan</a> (ERA) and 40 mg of <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a> (PDE5I) with either agent alone [<a href="#rid30">30</a>]. The combined regimen, administered on average for 18 months, resulted in a 50 percent reduction in the rate of clinical failure (18 percent versus 31 percent) and improved exercise capacity (49 versus 24 meters). The reduction in clinical failure rate was primarily driven by decreased hospitalizations for progressive PAH (which portends a poor prognosis), rather than by improved survival or WHO functional class. Adverse events (eg, edema, headache, nasal congestion, anemia, and syncope) were reported more frequently in those receiving combination therapy (45 versus 30 percent), but rates of hypotension were similar.</p><p>This trial is the basis for recommending this <strong>particular</strong> combination in PAH patients with class II or III symptoms. However, clinicians should be aware that substituting with other drugs within the same family (eg, <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> plus <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a>) may not be associated with the same improved outcomes. As an example, the increased metabolism and consequent reduction in plasma concentration of sildenafil by bosentan may partly explain the contradictory outcomes associated with this combination [<a href="#rid31">31</a>]. In contrast, the lack of drug interaction between <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a> and <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">ambrisentan</a> may also explain why the outcomes reported in AMBITION were more robust. (See <a class="local">'Alternate oral combinations'</a> below.)</p><p class="headingAnchor" id="H1502461138"><span class="h4">Alternate oral combinations</span><span class="headingEndMark"> — </span>Other combination oral regimens of two agents from a different class  (<a class="graphic graphic_table graphicRef50798" href="/z/d/graphic/50798.html" rel="external">table 4</a>) are feasible in patients not suited to the <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">ambrisentan</a> and <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a> combination (eg, contraindications to the drug or adverse effects).</p><p>The strongest level of data support the following combinations:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Macitentan</strong><strong> plus </strong><strong>sildenafil</strong> – The SERAPHIN trial compared the oral ERA <a class="drug drug_general" data-topicid="91206" href="/z/d/drug information/91206.html" rel="external">macitentan</a> to placebo in 250 patients with moderate to severe PAH; 85 percent of patients had IPAH or CTD-PAH, and the majority were functional class II or III [<a href="#rid32">32,33</a>]. Approximately 60 percent of patients were already on a PDE5I (ie, combined therapy), mostly <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a>, and 40 percent were treatment-naïve (ie, single-agent therapy with macitentan). Over a two-year period, fewer patients treated with macitentan (3 mg or 10 mg daily) progressed or died on therapy (38 and 31 percent, respectively versus 46 percent) [<a href="#rid32">32</a>]. Exercise capacity and WHO functional class also improved with macitentan treatment. This benefit was observed independent of whether patients were on combination or single-agent oral therapy for PAH. The study was not powered to show a benefit in mortality as an independent outcome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tadalafil</strong><strong> plus </strong><strong>bosentan</strong> – The PHIRST trial randomly assigned 405 patients with mostly functional class II and III PAH, one-half of whom were on <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a>, to receive <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a> (2.5, 10, 20, or 40 mg) or placebo once daily for 16 weeks [<a href="#rid34">34</a>]. Tadalafil (40 mg) significantly increased the 6MWD and the time to clinical worsening, while also decreasing the incidence of clinical worsening and improving health related quality of life. In an uncontrolled extension trial, PHIRST-2, the improvement of the 6MWD was sustained for an additional 52 weeks [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Riociguat</strong><strong> plus </strong><strong>bosentan</strong> – A multicenter randomized placebo-controlled trial of <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">riociguat</a> (PATENT-1) studied 443 patients with symptomatic PAH (mostly WHO functional class II and III) [<a href="#rid36">36</a>]. Approximately 50 percent were treatment-naïve and the remainder were on PAH-specific therapy, primarily the ERA, <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a>. Twelve weeks of oral riociguat (2.5 mg three times daily) resulted in a modest increase in the 6MWD (increase by 30 meters versus decrease by 6 meters) compared with placebo. Riociguat also resulted in improvements in pulmonary vascular resistance, symptoms, WHO functional class, and time to clinical worsening. This benefit was observed regardless of whether patients were receiving concurrent or single-agent PAH-specific therapy. A follow-up long-term extension study (PATENT-2) reported sustained benefits and a similar safety profile for riociguat when administered for up to two years [<a href="#rid37">37,38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selexipag</strong><strong> plus ERA and/or PDE5I</strong> – In a large trial (GRIPHON), 1156 patients with group 1 PAH and WHO classification II or III were randomly assigned to receive placebo or <a class="drug drug_general" data-topicid="106041" href="/z/d/drug information/106041.html" rel="external">selexipag</a> (200 to 1600 micrograms twice daily) for a median duration of 1.4 years [<a href="#rid39">39</a>]. The majority (approximately 80 percent) were receiving a stable dose of an ERA, a PDE5I, or both and the remainder were drug-naïve. Selexipag resulted in a benefit that was largely driven by a reduction in hospitalizations (14 versus 19 percent) and disease progression (7 versus 17 percent), rather than by improved survival (mortality, 5 versus 3 percent). The effect of selexipag as an add-on on double combination background therapy had a similar effect [<a href="#rid40">40</a>].</p><p></p><p>Other combinations have less robust evidence to support their use:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bosentan</strong><strong> plus </strong><strong>sildenafil</strong> – Unlike <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">ambrisentan</a> and <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a>, results from trials that combine <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> and <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a> have been contradictory. In one prospective study, the addition of sildenafil to bosentan in PAH patients who developed clinical deterioration, improved symptoms, exercise capacity, and WHO functional class [<a href="#rid41">41</a>]. Improvement was more frequent and of greater magnitude in patients with IPAH, compared with patients with scleroderma-associated PAH. In a second study of patients failing monotherapy with either bosentan or sildenafil, the addition of either agent also resulted in improved functional class and survival in those with IPAH, compared with those with connective tissue-associated PAH [<a href="#rid42">42</a>]. In contrast, a larger placebo-controlled trial reported no benefit when bosentan was added to sildenafil in a similar population, although the inclusion of patients with repaired congenital heart disease may have impacted the outcome [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral </strong><strong>treprostinil</strong><strong> plus ERA, </strong><strong>riociguat</strong><strong>,</strong> <strong>or PDE5I</strong> – The addition of oral <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a> in patients with group 1 PAH on an ERA and/or a phosphodiesterase-5 inhibitor did not improve the 6MWD at 16 weeks (FREEDOM-C and FREEDOM C-2) [<a href="#rid44">44-46</a>]. A study drug discontinuation rate of 22 percent was noted in the treprostinil group and was attributed to the high incidence (&gt;40 percent) of side effects of headache, nausea, vomiting, diarrhea, flushing, and jaw pain. Significant improvements were noted in dyspnea and exercise capacity. Another randomized trial (FREEDOM-EV) reported that oral treprostinil added to any other oral agent (most were on a PE5I or <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">riociguat</a>) resulted in a greater proportion of patients with improved time to clinical worsening when compared with the addition of placebo (26 versus 36 percent) [<a href="#rid47">47</a>]. However, the magnitude of the improvement was small.</p><p></p><p>Combinations of PDE5Is and <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">riociguat</a> are <strong>not</strong> recommended based upon post-trial data that demonstrated increased rates of hypotension (PATENT-PLUS) among patients taking this combination [<a href="#rid48">48</a>]. Consequently, the US Food and Drug Administration issued a warning against combining PDE5Is and guanylate cyclase stimulants [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H3537140895"><span class="h3">Single-agent therapy</span><span class="headingEndMark"> — </span>Occasionally, single-agent oral therapy may be appropriate for patients with very early class I/II disease who have a low-risk profile (see <a class="local">'WHO functional class I (monotherapy)'</a> above) and for patients who have been stable on monotherapy for a prolonged period (eg, 5 to 10 years). Other possible indications include patients &gt;75 years old with multiple risk factors for heart failure, patients suspected to have pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis, patients with contraindications to combination therapy (eg, severe liver disease), patients with portopulmonary hypertension and human immune deficiency virus (ie, patients who were not included in the combination trials), or patients who decline combination therapy. Selecting an agent is at the discretion of the prescribing PH-specialist.</p><p>For patients with functional class III symptoms who have rapid progression or other markers of poor clinical prognosis (eg, echocardiographic evidence of severe right ventricular dilatation and dysfunction or the presence of a pericardial effusion  (<a class="graphic graphic_table graphicRef123025" href="/z/d/graphic/123025.html" rel="external">table 6</a>)), we frequently initiate a parenteral or inhaled prostanoid, although starting an oral prostanoid (eg, <a class="drug drug_general" data-topicid="106041" href="/z/d/drug information/106041.html" rel="external">selexipag</a>, <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a>) is reasonable as an initial trial. In the latter situation, the threshold to switch to a parenteral agent should be low if patients worsen rapidly. (See <a class="local">'Parenteral prostanoid'</a> below.)</p><p class="headingAnchor" id="H3950411790"><span class="h4">Endothelin receptor antagonists</span><span class="headingEndMark"> — </span>Endothelin-1 is a potent vasoconstrictor and smooth muscle mitogen. Endothelin receptors A and B are targeted by endothelin receptor antagonists (ERAs). Nonselective dual-action ERAs include <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a> and <a class="drug drug_general" data-topicid="91206" href="/z/d/drug information/91206.html" rel="external">macitentan</a>, while <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">ambrisentan</a> is a selective antagonist of endothelin receptor A. Sitaxsentan was withdrawn from the European Union, Canada, and Australia in 2010 following several fatal cases of hepatoxicity [<a href="#rid50">50-54</a>].</p><p>Data supporting a role for individual ERAS as single-agent therapy include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>ERAs as a group</strong> – In a Cochrane meta-analysis of 16 randomized trials that compared ERAs with placebo in patients with functional class II/III, patients receiving ERAs had improved exercise capacity (mean increase of 25 m), functional class (odds ratio [OR] 1.41, 95% CI 1.16-1.70), and symptoms, and reduced odds of functional class deterioration (OR 0.43, 95% CI 0.26-0.72) [<a href="#rid55">55</a>]. There was low certainty evidence of a possible reduction in mortality from ERA use (OR 0.78, 95% CI 0.58, 1.07).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ambrisentan</strong> – Randomized placebo-controlled studies (eg, ARIES-1 and ARIES-2) of patients with moderate to severe idiopathic and CTD–related PAH (mostly WHO functional class II and III) consistently reported that <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">ambrisentan</a>, administered for up to two years, delayed disease progression and clinical worsening [<a href="#rid56">56-58</a>]. In addition, ambrisentan has been associated with improved exercise tolerance, WHO functional class, pulmonary vascular hemodynamics, and quality of life.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bosentan</strong> – <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">Bosentan</a> has been shown in patients with group 1 PAH to delay clinical worsening and improve pulmonary vascular hemodynamics and exercise capacity [<a href="#rid59">59-62</a>]. The mortality of bosentan-treated IPAH patients appears favorable compared with historical controls [<a href="#rid61">61,63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Macitentan</strong> – In the SERAPHIN trial that compared oral <a class="drug drug_general" data-topicid="91206" href="/z/d/drug information/91206.html" rel="external">macitentan</a> with placebo in 250 patients with moderate to severe PAH (mostly, WHO functional class II and III), the benefits that were observed in the patients taking combined therapy (eg, slower disease progression and lower mortality, improved exercise tolerance) were also seen in subgroup of patients that were on single-agent therapy with macitentan [<a href="#rid32">32,33</a>]. This trial is discussed in more detail above. (See <a class="local">'Alternate oral combinations'</a> above.)</p><p></p><p>The main adverse effects of ERAs are hepatotoxicity and peripheral edema [<a href="#rid32">32,54,56-58,60,64,65</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatotoxicity – Reports suggest that mild elevations in aminotransferase levels occur in less than 6 percent of patients on <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a>, <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">ambrisentan</a>, and <a class="drug drug_general" data-topicid="91206" href="/z/d/drug information/91206.html" rel="external">macitentan</a>. Ambrisentan appears to be the least hepatotoxic. For macitentan, rates of liver function test abnormalities were shown in trials to be no different between the treatment and placebo groups (3 to 4 percent), although post-marketing analysis suggests an increased risk of liver injury [<a href="#rid66">66</a>]. It is prudent to monitor liver function tests monthly during treatment with bosentan and occasionally with ambrisentan and macitentan. The duration of monitoring is indefinite for bosentan. In patients with moderate or severe hepatic dysfunction or patients on <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">glyburide</a>, we avoid or use caution when administering ERAs (eg, use ambrisentan rather than bosentan).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral edema – Peripheral edema is the most common side effect in patients taking <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a> and <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">ambrisentan</a> (up to 17 percent of patients); edema appears to be less of an issue with <a class="drug drug_general" data-topicid="91206" href="/z/d/drug information/91206.html" rel="external">macitentan</a>. Mild cases can be managed with diuretics, but more severe cases warrant discontinuation of the medication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Others – ERAs are also potent teratogens, requiring meticulous, double method contraception if used by women with childbearing potential. <a class="drug drug_general" data-topicid="91206" href="/z/d/drug information/91206.html" rel="external">Macitentan</a> may also be complicated by nasopharyngitis (15 percent) and anemia (8 percent) [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">Ambrisentan</a> should not be used in patients with concurrent idiopathic pulmonary fibrosis since one randomized trial reported that ambrisentan was associated with an increased risk of disease progression and hospitalizations [<a href="#rid67">67</a>]. This trial and treatment of interstitial lung disease-associated PH are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">"Treatment of idiopathic pulmonary fibrosis", section on 'Endothelin receptor antagonists'</a> and  <a class="medical medical_review" href="/z/d/html/8258.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H577486712"><span class="h4">Nitric oxide-cyclic guanosine monophosphate enhancers</span><span class="headingEndMark"> — </span>Agents in this class enhance the production or function of nitric oxide (NO), a potent vasodilator, and include phosphodiesterase inhibitors (PDE5Is) and the guanylate cyclase stimulant, <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">riociguat</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PDE5Is</strong> – One meta-analysis of 36 studies (2999 patients) reported that patients with group 1 PAH treated with PDE5Is were more likely to improve their WHO functional class (OR 8.59, 95% CI 3.95-18.72) and less likely to die (OR 0.088, 95% CI 0.07-0.68) [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sildenafil</strong> – <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">Sildenafil</a> improves pulmonary hemodynamics and exercise capacity in patients with group 1 PAH [<a href="#rid69">69-72</a>]. However, its effect on mortality has not been adequately evaluated. An illustrative trial (SUPER-1) randomly assigned 277 patients with group 1 PAH to receive sildenafil (20, 40, or 80 mg) or placebo three times daily for 12 weeks [<a href="#rid71">71</a>]. The sildenafil group demonstrated significant improvement in hemodynamics and 6MWD, which persisted during one year of follow-up. Mortality was not reported. A follow-up open-label, three-year extension trial (SUPER-2) [<a href="#rid73">73</a>] reported persistent improvement in the 6MWD and WHO functional class in 46 and 29 percent of patients, respectively; the estimated three year survival rate was 79 percent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tadalafil</strong> – In the PHIRST-1 and -2 trials that included 405 PAH patients, one-half of whom were treatment naïve, <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a> (40 mg) increased the 6MWD the time to clinical worsening, when compared with placebo [<a href="#rid34">34,35</a>]. These trials are discussed in detail above. (See <a class="local">'Alternate oral combinations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vardenafil</strong> – <a class="drug drug_general" data-topicid="10172" href="/z/d/drug information/10172.html" rel="external">Vardenafil</a> is not approved by the US Food and Drug Administration for the treatment of PAH but in PAH patients has been reported to increase the mean 6MWD and cardiac index, while decreasing the mean pulmonary arterial pressure, pulmonary vascular resistance, and number of clinical worsening events [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1">Adverse effects of PDE5Is and precautions that should be taken in those being treated with PDE5Is are similar to those in patients being treated for erectile dysfunction. Common side effects include headache, gastrointestinal upset, flushing, and muscle and joint pains. Further details are provided separately. (See  <a class="medical medical_review" href="/z/d/html/7469.html" rel="external">"Treatment of male sexual dysfunction", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Guanylate cyclase stimulant</strong> — <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">Riociguat</a> is an oral soluble guanylate cyclase stimulant that has reported benefit in patients with inoperable and persistent chronic thromboembolic PH (group 4) (see  <a class="medical medical_review" href="/z/d/html/16628.html" rel="external">"Chronic thromboembolic pulmonary hypertension: Pulmonary hypertension-specific therapy"</a>), but patients with group 1 PAH may also benefit from riociguat [<a href="#rid29">29,37,38</a>]. In trials of WHO class II and III PAH patients (PATENT-1 and -2), one-half of whom were treatment-naïve, riociguat (2.5 mg three times daily) improved the exercise tolerance, pulmonary vascular resistance, symptoms, WHO functional class, and time to clinical worsening for up to two years of treatment [<a href="#rid37">37,38</a>]. Riociguat had a favorable safety profile and was well tolerated, with syncope as the most frequent reported side effect (4 versus 1 percent). Hemoptysis from pulmonary hemorrhage was rare. This study is discussed in detail above. (See <a class="local">'Alternate oral combinations'</a> above.)</p><p></p><p class="headingAnchor" id="H2128194156"><span class="h4">Oral prostacyclin receptor agonists</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="106041" href="/z/d/drug information/106041.html" rel="external">Selexipag</a> is an oral selective <strong>non-prostanoid</strong> prostacyclin receptor (IP receptor) agonist that results in vasodilation of the pulmonary vascular bed and may benefit patients with PAH who have WHO functional class II and III [<a href="#rid39">39,75</a>]. Selexipag possesses high selectivity for the IP receptor over other prostanoid receptors distinguishing it from prostacyclin and prostacyclin analogs currently used in the management of PAH [<a href="#rid76">76</a>]. Best illustrating efficacy is a randomized trial (GRIPHON), where selexipag was associated with a reduction in hospitalizations and slower disease progression; however, only 20 percent of PAH patients were treatment naïve and the remainder were on other oral agents [<a href="#rid39">39</a>]. This study is discussed in more detail above (see <a class="local">'Alternate oral combinations'</a> above). An intravenous formulation is available for patients who are unable to temporarily take the oral formulation [<a href="#rid77">77</a>].</p><p>An oral formulation of <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a>, a prostacyclin analogue, has also been shown to improve exercise capacity in treatment-naïve PAH patients who have functional class II and III symptoms [<a href="#rid78">78-82</a>]. In contrast, conflicting data exist on the addition of oral treprostinil to other oral agents (FREEDOM trials) [<a href="#rid44">44-46</a>]. These data are discussed above. (See <a class="local">'Alternate oral combinations'</a> above.)</p><p class="headingAnchor" id="H244328232"><span class="h2">WHO functional class IV or high risk (parenteral prostanoid-containing combination regimen)</span><span class="headingEndMark"> — </span>Patients with severe PAH who are WHO functional class IV or high-risk PH should be treated with a parenteral prostanoid-containing combination regimen. Most of these patients are already receiving single or combination oral therapy from treatment administered for class III symptoms and the parenteral prostanoid is added to that regimen (resulting typically in triple combination therapy). Most clinicians consider intravenous (IV) <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a> as the preferred agent. IV or subcutaneous <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a> is a reasonable alternative. For patients who decline or cannot receive IV or subcutaneous therapy, inhaled treprostinil or <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">iloprost</a> is an option. It is prudent in this population to refer patients for lung transplantation evaluation. (See <a class="local">'Lung transplantation'</a> below.)</p><p class="headingAnchor" id="H3448020466"><span class="h3">Parenteral prostanoid</span><span class="headingEndMark"> — </span>Several parenteral prostanoids are available with the strongest evidence of efficacy in favor of IV <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a>. A meta-analysis of 17 trials (765 patients with PAH), patients on prostacyclin agonists were over twice as likely to have improved WHO functional class, 6MWD (19.5 meters, 95% CI 14.82-24.19), and pulmonary hemodynamics, compared with a control group of PAH patients (placebo, any other treatment or usual care) [<a href="#rid83">83</a>]. Mortality was improved in patients receiving IV agents (OR 0.29, 95% CI 0.12-0.69; risk of death 6 per 100). However, many of the studies were small or open-label randomized studies, which limit the certainty of the effect.</p><p class="headingAnchor" id="H915982381"><span class="h4">Epoprostenol</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – In patients with PAH, IV <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a> (prostacyclin; PGI<sub>2</sub>) consistently improves hemodynamic parameters and functional capacity, but only patients with IPAH have been shown to have improved survival with this drug; studies in other populations of PAH patients were limited [<a href="#rid83">83-93</a>]. The efficacy of IV epoprostenol was illustrated by a landmark trial that randomly assigned 81 patients with WHO class III or IV IPAH (three-quarters and one-quarter, respectively) to receive IV epoprostenol as single-agent therapy or standard therapy (typically oral therapy) for 12 weeks [<a href="#rid86">86</a>]. IV epoprostenol improved quality of life, mean pulmonary arterial pressure (-8 versus +3 percent), pulmonary vascular resistance (-21 versus +9 percent), and exercise capacity (+47 versus -66 meters). Eight patients died during the trial, all of whom were in the standard therapy group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong> – <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">Epoprostenol</a> is delivered continuously through a permanently implanted central venous catheter using a portable infusion pump. It is usually initiated, as an outpatient, at doses of 1 to 2 ng/kg per minute and increased by 1 to 2 ng/kg per minute every one to two days depending on symptoms and adverse effects. Once an initial level of 6 to 10 ng/kg per minute is achieved (usually within one to two weeks), most patients require dose increases of 1 to 2 ng/kg per minute every two to four weeks to sustain the clinical effect  (<a class="graphic graphic_table graphicRef50798" href="/z/d/graphic/50798.html" rel="external">table 4</a>). The rate at which the dose can be increased and peak dose varies from patient to patient and depends upon disease severity, symptoms, and adverse effects. For example, in some patients, a "plateau" is reached between 20 and 40 ng/kg per minute, while in others the dose may need further titration [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent1">A maximal dose has not been established. Patients who have been receiving therapy for many years may receive doses as high as 150 to 200 ng/kg per minute with sustained clinical and hemodynamic benefit. Excess doses may produce high-output cardiac states. In this situation, the dose should be reduced, while monitoring for rebound PH [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Side effects include jaw pain, diarrhea, flushing, and arthralgias. More severe adverse effects are usually attributable to the complex delivery system including thrombosis, pump malfunction, and interruption of the infusion. Central venous catheter infection occur in approximately 2 percent of patients annually and can also contribute to the morbidity and mortality of continuous <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a> therapy [<a href="#rid83">83,96-98</a>]. While interruption of the infusion can precipitate a life-threatening crisis from rebound PH, it is less commonly encountered now that patients are also frequently taking oral meds. (See  <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'Management of acute pulmonary hypertensive crisis'</a>.)</p><p></p><p class="headingAnchor" id="H1264341893"><span class="h4">Treprostinil</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">Treprostinil</a> is a prostacyclin analog that can be given IV or subcutaneously  (<a class="graphic graphic_table graphicRef50798" href="/z/d/graphic/50798.html" rel="external">table 4</a>). An inhaled and oral formulation are also available. Advantages of parenteral treprostinil, compared with <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a>, include the option of continuous subcutaneous rather than IV delivery for a small percentage of patients, a longer half-life such that cartridges only need changing every 48 rather than 24 hours. For patients who desire the advantages associated with treprostinil administration, it can be offered as first-line therapy. Patients who are already receiving epoprostenol can generally be transitioned to treprostinil (subcutaneous or intravenous) without a significant loss of clinical efficacy [<a href="#rid99">99,100</a>]. Reciprocally, epoprostenol can be given if the desired effect is not achieved with treprostinil.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – IV and subcutaneous <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a> improve hemodynamic parameters, symptoms, exercise capacity, and, possibly, survival in patients with group 1 PAH [<a href="#rid78">78-82</a>]. Trials comparing <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a> with treprostinil have not been performed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">Treprostinil</a> is delivered continuously through a subcutaneous or IV catheter using a portable infusion pump. It is usually initiated, as an outpatient. Subcutaneous or IV dosing infusions are started at 0.625 to 1.25 ng/kg per minute. The dose is increased in increments of 1.25 ng/kg per minute per week for first four weeks, followed by increments of 2.5 ng/kg per minute per week for remainder of therapy. Similar to <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a>, the maximal dose has not been established.</p><p></p><p class="bulletIndent1">Rapid uptitration of <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a> has been described in 17 pregnant women with severe PAH/PH crisis [<a href="#rid101">101</a>]. IV treprostinil was started at 1.25 ng/kg per minute and increased by 1.5 to 2.5 ng/kg per minute every three hours to a maximum dose of 10 ng/kg per minute during the first 24 hours. During the next 24 hours the dose was similarly increased to a median maximum dose of 15 ng/kg per minute (interquartile range, 15 to 20 ng/kg per minute). Fifteen patients survived to discharge, and only two died of their PH crisis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The adverse effects of <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a> are similar to those of <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a>. Subcutaneous administration is used less often than in the past due to severe pain at the injection site.</p><p></p><p>Studies describing the efficacy of inhaled <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a> are discussed below. (See <a class="local">'Combination therapy containing a parenteral agent'</a> below.)</p><p class="headingAnchor" id="H511417592"><span class="h4">Iloprost</span><span class="headingEndMark"> — </span>Inhaled <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">iloprost</a>, a prostacyclin analogue, has theoretical advantages in that it specifically targets the lung vasculature and does not require IV administration  (<a class="graphic graphic_table graphicRef50798" href="/z/d/graphic/50798.html" rel="external">table 4</a>). The main disadvantages are the need for frequent administration (six to nine times per day), peaks and lows of drug concentration, and inability to dose during sleep.</p><p class="bulletIndent1">One trial randomly assigned 203 patients with PAH (including a variety of types) who were WHO class III or IV to receive <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">iloprost</a> (2.5 to 5 mcg, six to nine times per day) or placebo for 12 weeks [<a href="#rid102">102</a>]. Greater improvements in WHO class and in the 6MWD was reported in the iloprost group compared with the placebo group (17 versus 5 percent).</p><p></p><p class="headingAnchor" id="H1107631919"><span class="h3">Combination therapy containing a parenteral agent</span><span class="headingEndMark"> — </span>While in the past, single-agent therapy was common, most patients now with WHO functional class IV are on combination therapy from treatment administered for class III symptoms and, in general, previous medications are not discontinued. Among the possible combinations, many experts prefer IV <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a> added to a PDE5I (eg, <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a>, <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a>).</p><p>Several combinations have been shown to be beneficial in patients with PAH:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sildenafil</strong><strong> added to </strong><strong>epoprostenol</strong> – One trial randomly assigned 267 patients with group 1 PAH who were receiving <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a> to have <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> or placebo added for 16 weeks [<a href="#rid103">103</a>]. Most patients were WHO functional class III at the beginning of the trial. Sildenafil improved hemodynamic parameters, exercise capacity, quality of life, and time to clinical worsening, compared with placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bosentan</strong><strong> added to either </strong><strong>epoprostenol</strong><strong> or </strong><strong>treprostinil</strong> – One trial (BREATHE-2 trial) randomly assigned 22 patients with group 1 PAH who were receiving <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a> to have either <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a> or placebo added for 16 weeks [<a href="#rid104">104</a>]. Epoprostenol improved hemodynamic parameters, exercise capacity, and functional class, compared with baseline. The addition of bosentan improved these outcomes to a greater degree than the addition of placebo, although the difference was not statistically significant [<a href="#rid81">81,104</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhaled </strong><strong>treprostinil</strong><strong> added to either </strong><strong>bosentan</strong><strong> or </strong><strong>sildenafil</strong> – In one trial (TRIUMPH), 235 patients with group 1 PAH who were deteriorating despite <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a> or <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> therapy were randomly assigned to receive the addition of either inhaled <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a> or placebo for 12 weeks [<a href="#rid105">105</a>]. The treprostinil group had a significant improvement in their 6MWD and quality of life, but there were no differences in the time to clinical worsening, dyspnea, or WHO functional class.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sildenafil</strong><strong> added to inhaled </strong><strong>iloprost</strong> – Several studies have shown that in patients with group 1 PAH have reported that the addition of <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> to inhaled <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">iloprost</a> resulted in an improvement in exercise capacity, WHO functional class, and hemodynamics [<a href="#rid106">106,107</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bosentan</strong><strong> plus inhaled </strong><strong>iloprost</strong> – The effect of combining <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a> with <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">iloprost</a> is less clear. Early observational studies suggested that the combination was both safe and effective when bosentan was added to preexisting inhaled iloprost therapy [<a href="#rid108">108</a>]. However, a subsequent trial that randomly assigned 40 patients with IPAH to receive bosentan alone or bosentan plus iloprost for 12 weeks, demonstrated no difference in the 6MWD [<a href="#rid109">109</a>]. The results of the trial may have been skewed by three outliers in the combination therapy group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Others</strong> – Small numbers of patients with functional class IV PAH were included in PATENT (<a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">riociguat</a>) and SERAPHIN (<a class="drug drug_general" data-topicid="91206" href="/z/d/drug information/91206.html" rel="external">macitentan</a>) and are insufficient to draw conclusions [<a href="#rid32">32,36</a>]. These trials are discussed above. (See <a class="local">'Alternate oral combinations'</a> above.)</p><p></p><p class="headingAnchor" id="H2172512708"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Initiation of PH-specific therapy (including calcium channel blocker [CCB] therapy) requires close follow-up. Frequent reassessment is necessary because of the complex nature of the disease and its treatments, as well as the tendency of PAH to progress.</p><p class="headingAnchor" id="H4238803538"><span class="h2">Outpatients visits</span><span class="headingEndMark"> — </span>Patients should be seen as an outpatient in a PH center, but patient logistics may dictate alternative forms of follow-up, such as frequent telephone contact and co-management with local clinicians.</p><p>The initial visit usually occurs within the first six weeks. Thereafter, patients should ideally be seen every three months. However, for patients receiving parenteral or combination therapy and patients who have advanced symptoms, right heart failure, or advanced hemodynamic abnormalities, more frequent visits are typical.</p><p>Follow-up visits should ideally include a thorough history and examination to assess symptoms of right heart failure, exercise tolerance, and resting and ambulatory oximetry. The frequency of follow-up testing with brain natriuretic peptide (BNP or N-terminal pro-BNP [NT-proBNP]), six-minute walk distance (6MWD), echocardiogram, and right heart catheterization should be determined on a case-by-case basis and varies among centers. We usually obtain a 6MWD at each visit and an echocardiogram every 12 months, or sooner if clinically indicated. In addition, we typically repeat a right heart catheterization after the initiation of therapy (eg, at 3, 6, or 12 months), as well as when the patient deteriorates. The threshold to obtain BNP or NT-proBNP should be low, especially in patients with a deterioration in clinical status [<a href="#rid110">110,111</a>].</p><p>Patients should be warned not to stop their medication suddenly, particularly intravenous <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a>, since abrupt increases in pulmonary pressures may occur resulting in acute deterioration, especially if they are receiving single-agent therapy. Patient education and medication-alert devices for this purpose are prudent. (See  <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'Management of acute pulmonary hypertensive crisis'</a>.)</p><p>For patients who require surgery or a procedure, perioperative/procedural management of PAH-specific medications should be done in conjunction with a PH expert and anesthesiologist, the details of which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/94362.html" rel="external">"Anesthesia for noncardiac surgery in patients with pulmonary hypertension or right heart failure"</a> and  <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'Management of acute pulmonary hypertensive crisis'</a> and  <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'Surgical or periprocedural care'</a>.)</p><p class="headingAnchor" id="H2881265055"><span class="h2">Goal-oriented therapy</span><span class="headingEndMark"> — </span>A good response to therapy is typically considered one that involves improvement in all of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Functional class, preferably to class I or low-risk category</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Echocardiographic and biochemical evidence of right heart failure (ie, "goal-oriented" therapy)</p><p></p><p>Improvements should be notable within the first six weeks of therapy but may continue to occur over three to six months or longer. Rare patients have an extraordinary response, but de-escalation of therapy is not routinely recommended. However, for patients who experience a suboptimal response (eg, minor improvement, stabilize without progression), or develop progressive symptoms on therapy (even after a period of stability), escalation therapy is warranted.</p><p class="headingAnchor" id="H1807579715"><span class="h2">Escalation therapy</span><span class="headingEndMark"> — </span>Escalation therapy involves increasing the dose of a current medication and/or the addition of a second agent (for patients on monotherapy) or a third agent (for patients on double combination therapy). CCBs are not generally considered part of double or triple therapy. Importantly, combining two agents from the same class is contraindicated (eg, phosphodiesterase 5 inhibitor [PDE5I] and <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">riociguat</a> <strong>or</strong> oral <a class="drug drug_general" data-topicid="106041" href="/z/d/drug information/106041.html" rel="external">selexipag</a> and parenteral prostanoid).</p><p>Escalation of therapy and transitioning from one agent to another, which is sometimes needed (eg, for adverse effects or noncompliance), should always be done under the supervision of an expert in PAH.</p><p>Switching to another agent in the same class may be an option for those on nitric oxide-cyclic guanosine enhancers. One preliminary study suggested that switching from a PDE5I to <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">riociguat</a> was safe and a potential approach to escalation therapy [<a href="#rid112">112</a>]. In that study, 293 patients on a PDE5I were randomly switched to riociguat or continuation of their PDE5I. More patients in the riociguat group improved compared with those who stayed on their PDE5I (41 versus 21 percent).</p><p>Patients who are rapidly deteriorating despite therapy should be referred for lung transplantation (eg, patient may have unrecognized pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis). (See <a class="local">'Lung transplantation'</a> below.)</p><p class="headingAnchor" id="H2150081123"><span class="h1">REFRACTORY PATIENTS</span><span class="headingEndMark"> — </span>PAH is a progressive disease, and, in some cases, patients progress to a point where they are refractory to PAH-specific therapy. Such patients have a high mortality. Lung transplantation is a definitive form of therapy for such cases, while the creation of a right-to-left shunt is a temporizing measure only.</p><p class="headingAnchor" id="H1336334212"><span class="h2">Lung transplantation</span><span class="headingEndMark"> — </span>Guidelines for lung transplant <strong>referral</strong> are as follows [<a href="#rid113">113</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>World Health Organization (WHO) functional class III or IV during escalating therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Rapidly progressive disease (prior to or on therapy)</p><p class="bulletIndent1"><span class="glyph">●</span>Use of parenteral prostanoid therapy regardless of functional class symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Known or suspected pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis</p><p></p><p>Bilateral lung or heart-lung transplantation is the procedure of choice [<a href="#rid114">114</a>]. Selection of suitable patients for lung transplantation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">"Lung transplantation: General guidelines for recipient selection"</a> and  <a class="medical medical_review" href="/z/d/html/4659.html" rel="external">"Lung transplantation: An overview"</a>.)</p><p>Post-transplantation management for idiopathic PAH (IPAH) is similar to management for other conditions requiring transplantation, although the incidence of obliterative bronchiolitis appears to be higher in IPAH patients undergoing transplantation [<a href="#rid115">115</a>]. An elevated bilirubin has been associated with a high postoperative mortality in heart-lung transplant recipients, and the likelihood of successful transplantation is poor if the bilirubin elevation persists after the patient's cardiopulmonary status is optimized. Recurrence of IPAH after transplantation has not been reported. (See  <a class="medical medical_review" href="/z/d/html/4651.html" rel="external">"Lung transplantation: Procedure and postoperative management"</a>.)</p><p>Although lung transplantation has been successfully performed in patients with IPAH and is considered a definitive therapy [<a href="#rid114">114,116,117</a>], it is not necessarily associated with improved survival. The three-year survival of patients who had a lung or heart-lung transplant for IPAH is approximately 50 percent [<a href="#rid118">118,119</a>].</p><p>Indications for liver transplantation in patients with portopulmonary hypertension are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8266.html" rel="external">"Portopulmonary hypertension", section on 'Liver transplantation'</a>.)</p><p class="headingAnchor" id="H455985121"><span class="h2">Right-to-left shunt</span><span class="headingEndMark"> — </span>Creation of a right-to-left shunt is a temporizing (eg, as a bridge to transplant) or palliative measure. It is typically reserved for patients with severe symptomatic PAH and right heart failure, despite aggressive advanced therapy and maximal diuretic therapy [<a href="#rid118">118,120</a>]. It may also be considered in patients who have signs of impaired systemic blood flow (such as syncope) due to reduced left heart filling. The purpose of right-to-left shunting is to avoid these undesirable outcomes by diverting blood flow to bypass the pulmonary vascular bed and enter the systemic circulation, thereby elevating systemic blood flow and maintaining tissue perfusion, albeit with less oxygenated blood. They are rarely performed in the United States but more commonly performed in countries where transplant is an infrequent option.</p><p>Procedures that have been used to generate a right-to-left shunt in adults with PAH are atrial septostomy and placement of a Potts shunt via a transcatheter approach [<a href="#rid118">118,121-130</a>]. Importantly, a preexisting patent foreman ovale or atrial septal defect (may act as a natural right-to-left shunt in those with severe PAH) should not be percutaneously or surgically closed in a patient with significant PH.</p><p>Shunts are not reversible and require surgical closure at the time of transplant.</p><p class="headingAnchor" id="H96612761"><span class="h3">Atrial septostomy</span><span class="headingEndMark"> — </span>Atrial septostomy is a right-to-left shunt that connects right and left atrial cavities. Although arterial desaturation follows the procedure, it may be offset in some patients by increased cardiac output and augmentation of systemic oxygen delivery [<a href="#rid121">121,124,131</a>]. However, procedure-related mortality may be as high as 15 to 40 percent [<a href="#rid121">121,127</a>]. Stepwise balloon dilatation is the procedure of choice [<a href="#rid114">114</a>].</p><p>In a meta-analysis of 16 trials (204 patients), balloon atrial septostomy resulted in a reduction in right atrial pressure (-2.77 mmHg), increase in cardiac index (0.62 L/M/m<sup>2</sup>) and left atrial pressure (1.68 mmHg), and decrease in arterial saturation (-8.45 percent) [<a href="#rid131">131</a>]. Mortality at 30 days was 38 percent.</p><p>Patients with the most advanced PAH appear more likely to die or get worse with atrial septostomy. This includes patients with markedly elevated mean right atrial pressure (eg, greater than 20 mmHg) [<a href="#rid114">114</a>], extremely low cardiac output, and a resting arterial oxyhemoglobin saturation less than 80 percent. In addition, older age and impaired renal function were associated with early adverse outcomes in one series [<a href="#rid121">121</a>].</p><p class="headingAnchor" id="H3989956060"><span class="h3">Transcatheter Potts shunt</span><span class="headingEndMark"> — </span>Surgical placement of a right-to-left shunt between the left pulmonary artery and the descending aorta (Potts shunt) has been described as a palliative measure in children with PAH. However, mortality from general anesthesia and surgery in adult patients with severe PAH is considerably higher. Placement of a transcatheter Potts shunt (TPS) under fluoroscopic guidance has been performed in one pilot study [<a href="#rid130">130</a>]. TPS involves retrograde needle perforation of the aorta, with subsequent placement of a covered stent between the aorta and left pulmonary artery. Of four adults studied (18 to 47 years old), two died and two survived at 4 and 10 months with symptomatic improvement. The use of TPS should be reserved for patients enrolled in clinical trials until further studies confirm its safety and efficacy in this population.</p><p class="headingAnchor" id="H2772035527"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The prognosis of PAH is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H3954957263"><span class="h1">INVESTIGATIONAL THERAPIES</span><span class="headingEndMark"> — </span>Investigational therapies include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sotatercept </strong>– Mutations in bone morphogenetic protein receptor type 2 (<em>BMPR2)</em> play a known role in the pathogenesis of PAH. BMP is a member of the transforming growth factor (TGF) beta family of proteins. Sotatercept acts as a ligand trap for members of the TGF-beta superfamily, and restores balance between the growth-promoting activin pathway and the growth-inhibiting BMP pathway [<a href="#rid132">132</a>]. Preliminary data in phase 2 trials reported benefit from sotatercept [<a href="#rid133">133,134</a>]. In a phase 3 trial of 320 PAH patients on stable background therapy and with stable functional class II and III symptoms, sotatercept was compared with placebo [<a href="#rid135">135</a>]. Sotatercept resulted in improved six-minute walk distance (6MWD) at 24 weeks (median change 34.4 versus 1 meter). Improvements were also reported in pulmonary vascular resistance, N-terminal pro-B-type natriuretic peptide (NT-proBNP) level, WHO functional class, and time to death or clinical worsening. The most common adverse effects were headache, diarrhea, and peripheral edema. Specific to sotatercept were also increased hemoglobin level, thrombocytopenia, bleeding, telangiectasis, and hypertension. While encouraging, these patients were clinically stable; many had already received two or three other medications, and the majority had idiopathic or heritable PAH. Thus, generalizability to sicker, less clinically stable, or treatment-naïve patients is unknown. A post hoc analysis of this trial also showed improved pulmonary hemodynamics and right ventricular function [<a href="#rid136">136</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary artery denervation</strong> – Pulmonary artery denervation (PADN) has been studied in PAH. In one study of 128 patients, PADN in intermediate high-risk patients who were treated with a combination of PADN and PDE-5 inhibitors had greater improvement in the 6MWD, NT-proBNP, and pulmonary vascular resistance compared with those treated with sham plus PDE-5 inhibitor [<a href="#rid137">137</a>].</p><p></p><p class="headingAnchor" id="H703063396"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115503.html" rel="external">"Society guideline links: Pulmonary hypertension in adults"</a>.)</p><p class="headingAnchor" id="H35"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary arterial hypertension (PAH)-specific therapies</strong> – PAH-specific therapy (also known as PAH-targeted or PAH-directed therapy) is directed at the PAH itself rather than the underlying cause of the PAH. PAH-specific agents include prostacyclin pathway agonists (<a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a>, <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a>, <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">iloprost</a>, <a class="drug drug_general" data-topicid="106041" href="/z/d/drug information/106041.html" rel="external">selexipag</a>), endothelin receptor antagonists (ERAs; <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">ambrisentan</a>, <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">bosentan</a>, <a class="drug drug_general" data-topicid="91206" href="/z/d/drug information/91206.html" rel="external">macitentan</a>), nitric oxide-guanosine monophosphate (NO-cGMP) enhancers (phosphodiesterase 5 inhibitors [PDE5Is; <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a>, <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a>]), or, rarely, calcium channel blockers (CCBs; <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a>, <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a>)  (<a class="graphic graphic_table graphicRef50798" href="/z/d/graphic/50798.html" rel="external">table 4</a>). (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Agent selection</strong> – Patients with PAH should be referred to a specialized pulmonary hypertension (PH) center for evaluation and management. The diagnosis of PAH (and any potential associated etiology) should be in place and, when indicated, acute vasoreactivity testing (AVT) should be performed (idiopathic PAH, heritable PAH, and drug-induced PAH). Although agent selection based upon several risk stratification models has been proposed, we prefer to select PAH-specific therapy based upon AVT and World Health Organization (WHO) functional class  (<a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">table 5</a>) and, subsequently, individualize that therapy according to additional factors that can affect risk and patient preference  (<a class="graphic graphic_table graphicRef123025" href="/z/d/graphic/123025.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef123026" href="/z/d/graphic/123026.html" rel="external">table 7</a> and <a class="graphic graphic_algorithm graphicRef71168" href="/z/d/graphic/71168.html" rel="external">algorithm 1</a>). (See <a class="local">'Pretreatment evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Positive vasoreactivity</strong> – For patients who have a positive vasoreactivity test and WHO class I to III symptoms, we suggest a trial of CCB therapy with extended-release <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> or extended-release <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The rationale for a CCB trial is based upon the lower toxicity profile when compared with other PAH-specific therapies. However, the response rate is often suboptimal and typically not sustained. Patients who respond to CCB therapy should be reassessed after three to six months of treatment. Patients with WHO functional class IV do not generally undergo AVT and would be treated as if they were nonvasoreactive. (See <a class="local">'Calcium channel blockers (trial)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonvasoreactive</strong> – For patients with PAH who are typically nonvasoreactive (eg, connective tissue disease-PAH, human immune deficiency PAH) and have not undergone vasoreactive testing and for patients who are nonvasoreactive or are vasoreactive and have failed CCB therapy, PAH-specific therapy with a non-CCB agent depends upon WHO functional class  (<a class="graphic graphic_algorithm graphicRef71168" href="/z/d/graphic/71168.html" rel="external">algorithm 1</a>). (See <a class="local">'Nonvasoreactive patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>WHO functional class I</strong> – For patients with WHO functional class I symptoms, we suggest monotherapy with a PAH-specific agent (eg, PDE5I, ERA, or <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">riociguat</a>) rather than no treatment (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This is particularly important for "high-risk" patients  (<a class="graphic graphic_table graphicRef123025" href="/z/d/graphic/123025.html" rel="external">table 6</a>), based upon the rationale that, if left untreated, PAH will progress. Agent selection is at the discretion of the treating PH specialist. (See <a class="local">'WHO functional class I (monotherapy)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>WHO functional class II/III</strong> – For patients with WHO functional class II or III symptoms (ie, low- or intermediate-risk PH), we suggest dual combination oral therapy rather than monotherapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Combination therapy generally consists of an ERA and an agent that targets the NO-cGMP pathway, typically a PDE5I. Combination therapy appears to improve exercise capacity and reduce the rates of disease progression and hospitalization compared with monotherapy, although a mortality benefit has not been clearly demonstrated. Monotherapy may be suitable for a select group (eg, patients with very early class I/II disease). (See <a class="local">'WHO functional class II and III or low/intermediate risk (combination oral therapy)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For patients with WHO functional class IV</strong> – For patients with WHO functional class IV symptoms (ie, high-risk PH), we suggest treatment with a parenteral prostanoid-containing combination regimen rather than oral therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Combination therapy is typically triple or, less commonly, double therapy. Among the options for parenteral prostanoids, we suggest intravenous (IV) <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a> rather than other agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The rationale for this choice is that limited data support a possible survival advantage with epoprostenol therapy. IV or subcutaneous <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">treprostinil</a> is a reasonable alternative. Inhaled treprostinil or <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">iloprost</a> is an option for patients who decline or cannot receive IV or subcutaneous therapy. Early referral for lung transplantation is prudent in this population. (See <a class="local">'WHO functional class IV or high risk (parenteral prostanoid-containing combination regimen)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong> – After starting PAH-specific therapy, patients should be followed up within the first six weeks. Thereafter, patients should ideally be seen every three months. However, for patients receiving parenteral or combination therapy and patients who have advanced symptoms, right heart failure, or advanced hemodynamic abnormalities, more frequent visits are typical.</p><p></p><p class="bulletIndent1">A good response to therapy is typically considered one that involves improvement in functional class (preferably to class I), clinical symptoms, and echocardiographic and biochemical evidence of right heart failure (ie, "goal-oriented" therapy). For patients who experience a suboptimal response (eg, minor improvement, stabilize without progression), or develop progressive symptoms on therapy, escalation therapy is warranted (eg, dual or triple combination therapy). (See <a class="local">'Follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory patients</strong> – For patients who are refractory to medical therapy, lung transplantation is a definitive form of therapy, while the creation of a right-to-left shunt is a temporizing measure only. (See <a class="local">'Refractory patients'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43:3618.</a></li><li><a class="nounderline abstract_t">Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J 2010; 31:1898.</a></li><li><a class="nounderline abstract_t">Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338:1173.</a></li><li><a class="nounderline abstract_t">Morales-Blanhir J, Santos S, de Jover L, et al. Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 2004; 98:225.</a></li><li><a class="nounderline abstract_t">Sitbon O, Humbert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12:265.</a></li><li><a class="nounderline abstract_t">Ricciardi MJ, Knight BP, Martinez FJ, Rubenfire M. Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 1998; 32:1068.</a></li><li><a class="nounderline abstract_t">Atz AM, Adatia I, Lock JE, Wessel DL. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol 1999; 33:813.</a></li><li><a class="nounderline abstract_t">Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 2019; 53.</a></li><li><a class="nounderline abstract_t">Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest 2012; 141:354.</a></li><li><a class="nounderline abstract_t">Sitbon O, Benza RL, Badesch DB, et al. Validation of two predictive models for survival in pulmonary arterial hypertension. Eur Respir J 2015; 46:152.</a></li><li><a class="nounderline abstract_t">Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. Chest 2019; 156:323.</a></li><li><a class="nounderline abstract_t">Anderson JJ, Lau EM, Lavender M, et al. Retrospective Validation of the REVEAL 2.0 Risk Score With the Australian and New Zealand Pulmonary Hypertension Registry Cohort. Chest 2020; 157:162.</a></li><li><a class="nounderline abstract_t">Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J 2017; 50.</a></li><li><a class="nounderline abstract_t">Hoeper MM, Pausch C, Olsson KM, et al. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J 2022; 60.</a></li><li><a class="nounderline abstract_t">Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53.</a></li><li><a class="nounderline abstract_t">Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76.</a></li><li><a class="nounderline abstract_t">Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987; 76:135.</a></li><li><a class="nounderline abstract_t">Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351:1425.</a></li><li><a class="nounderline abstract_t">Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111:3105.</a></li><li><a class="nounderline abstract_t">Palevsky HI, Fishman AP. Chronic cor pulmonale. Etiology and management. JAMA 1990; 263:2347.</a></li><li><a class="nounderline abstract_t">Melot C, Hallemans R, Naeije R, et al. Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984; 130:612.</a></li><li><a class="nounderline abstract_t">Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160:600.</a></li><li><a class="nounderline abstract_t">Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004; 44:1488.</a></li><li><a class="nounderline abstract_t">Packer M, Medina N, Yushak M. Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. J Am Coll Cardiol 1984; 4:890.</a></li><li><a class="nounderline abstract_t">Galiè N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30:394.</a></li><li><a class="nounderline abstract_t">Rich S. The value of approved therapies for pulmonary arterial hypertension. Am Heart J 2007; 153:889.</a></li><li><a class="nounderline abstract_t">Galiè N, Rubin Lj, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371:2093.</a></li><li><a class="nounderline abstract_t">Shapiro S, Torres F, Feldman J, et al. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1). Respir Med 2017; 126:84.</a></li><li><a class="nounderline abstract_t">Wardle AJ, Seager MJ, Wardle R, et al. Guanylate cyclase stimulators for pulmonary hypertension. Cochrane Database Syst Rev 2016; :CD011205.</a></li><li><a class="nounderline abstract_t">Galiè N, Barberà JA, Frost AE, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med 2015; 373:834.</a></li><li><a class="nounderline abstract_t">Paul GA, Gibbs JS, Boobis AR, et al. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005; 60:107.</a></li><li><a class="nounderline abstract_t">Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369:809.</a></li><li><a class="nounderline abstract_t">Simonneau G, Channick RN, Delcroix M, et al. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. Eur Respir J 2015; 46:1711.</a></li><li><a class="nounderline abstract_t">Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119:2894.</a></li><li><a class="nounderline abstract_t">Oudiz RJ, Brundage BH, Galie N. Tadalafil for the Treatment of Pulmonary Arterial Hypertension. J Am Coll Cardiol 2012; Epub ahead of print.</a></li><li><a class="nounderline abstract_t">Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369:330.</a></li><li><a class="nounderline abstract_t">Rubin LJ, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J 2015; 45:1303.</a></li><li><a class="nounderline abstract_t">Ghofrani HA, Grimminger F, Grünig E, et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med 2016; 4:361.</a></li><li><a class="nounderline abstract_t">Sitbon O, Channick R, Chin KM, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2015; 373:2522.</a></li><li><a class="nounderline abstract_t">Coghlan JG, Channick R, Chin K, et al. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. Am J Cardiovasc Drugs 2018; 18:37.</a></li><li><a class="nounderline abstract_t">Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007; 29:469.</a></li><li><a class="nounderline abstract_t">Dardi F, Manes A, Palazzini M, et al. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights. Eur Respir J 2015; 46:414.</a></li><li><a class="nounderline abstract_t">McLaughlin V, Channick RN, Ghofrani HA, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015; 46:405.</a></li><li><a class="nounderline abstract_t">Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012; 142:1383.</a></li><li><a class="nounderline abstract_t">Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 2013; 127:624.</a></li><li><a class="nounderline abstract_t">Tapson VF, Jing ZC, Xu KF, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest 2013; 144:952.</a></li><li><a class="nounderline abstract_t">White RJ, Jerjes-Sanchez C, Bohns Meyer GM, et al. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. Am J Respir Crit Care Med 2020; 201:707.</a></li><li><a class="nounderline abstract_t">Galiè N, Müller K, Scalise AV, Grünig E. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J 2015; 45:1314.</a></li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/020895Orig1s045ltr.pdf (Accessed on September 21, 2015).</li><li><a class="nounderline abstract_t">Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47:2049.</a></li><li><a class="nounderline abstract_t">Wittbrodt ET, Abubakar A. Sitaxsentan for treatment of pulmonary hypertension. Ann Pharmacother 2007; 41:100.</a></li><li><a class="nounderline abstract_t">Seligman BG, Ribeiro RA, Kuchenbecker Rde S, et al. Critical steps in fluoroquinolones and carbapenems prescriptions: results from a prospective clinical audit. Int J Clin Pract 2007; 61:147.</a></li><li><a class="nounderline abstract_t">Benza RL, Barst RJ, Galie N, et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest 2008; 134:775.</a></li><li class="breakAll">Thelin (sitaxentan) to be withdrawn due to cases of unpredictable serious liver injury. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/12/WC500099707.pdf (Accessed on December 15, 2010).</li><li><a class="nounderline abstract_t">Liu C, Chen J, Gao Y, et al. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2021; 3:CD004434.</a></li><li><a class="nounderline abstract_t">Galié N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46:529.</a></li><li><a class="nounderline abstract_t">Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117:3010.</a></li><li><a class="nounderline abstract_t">Oudiz RJ, Galiè N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:1971.</a></li><li><a class="nounderline abstract_t">Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358:1119.</a></li><li><a class="nounderline abstract_t">Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896.</a></li><li><a class="nounderline abstract_t">McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25:244.</a></li><li><a class="nounderline abstract_t">Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003; 124:247.</a></li><li><a class="nounderline abstract_t">Channick RN, Sitbon O, Barst RJ, et al. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43:62S.</a></li><li><a class="nounderline abstract_t">McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009; 135:122.</a></li><li><a class="nounderline abstract_t">D'Alto M. An update on the use of ambrisentan in pulmonary arterial hypertension. Ther Adv Respir Dis 2012; 6:331.</a></li><li class="breakAll">https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&amp;linkID=SSR00220 (Accessed on March 22, 2019).</li><li><a class="nounderline abstract_t">Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013; 158:641.</a></li><li><a class="nounderline abstract_t">Barnes H, Brown Z, Burns A, Williams T. Phosphodiesterase 5 inhibitors for pulmonary hypertension. Cochrane Database Syst Rev 2019; 1:CD012621.</a></li><li><a class="nounderline abstract_t">Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84:E4.</a></li><li><a class="nounderline abstract_t">Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000; 343:1342.</a></li><li><a class="nounderline abstract_t">Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148.</a></li><li><a class="nounderline abstract_t">Pepke-Zaba J, Gilbert C, Collings L, Brown MC. Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. Chest 2008; 133:183.</a></li><li><a class="nounderline abstract_t">Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 2011; 140:1274.</a></li><li><a class="nounderline abstract_t">Jing ZC, Yu ZX, Shen JY, et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2011; 183:1723.</a></li><li><a class="nounderline abstract_t">Kim NH, Hemnes AR, Chakinala MM, et al. Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE. J Heart Lung Transplant 2021; 40:279.</a></li><li><a class="nounderline abstract_t">Kuwano K, Hashino A, Noda K, et al. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther 2008; 326:691.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/214275Orig1s000ltr.pdf (Accessed on August 03, 2021).</li><li><a class="nounderline abstract_t">Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 2006; 129:683.</a></li><li><a class="nounderline abstract_t">Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:800.</a></li><li><a class="nounderline abstract_t">Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006; 28:1195.</a></li><li><a class="nounderline abstract_t">Benza RL, Rayburn BK, Tallaj JA, et al. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan. Chest 2008; 134:139.</a></li><li><a class="nounderline abstract_t">Benza RL, Tapson VF, Gomberg-Maitland M, et al. One-year experience with intravenous treprostinil for pulmonary arterial hypertension. J Heart Lung Transplant 2013; 32:889.</a></li><li><a class="nounderline abstract_t">Barnes H, Yeoh HL, Fothergill T, et al. Prostacyclin for pulmonary arterial hypertension. Cochrane Database Syst Rev 2019; 5:CD012785.</a></li><li><a class="nounderline abstract_t">Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121:409.</a></li><li><a class="nounderline abstract_t">Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112:485.</a></li><li><a class="nounderline abstract_t">Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334:296.</a></li><li><a class="nounderline abstract_t">Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30:343.</a></li><li><a class="nounderline abstract_t">Higenbottam T, Butt AY, McMahon A, et al. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998; 80:151.</a></li><li><a class="nounderline abstract_t">Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40:780.</a></li><li><a class="nounderline abstract_t">Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159:1925.</a></li><li><a class="nounderline abstract_t">McLaughlin VV, Genthner DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999; 130:740.</a></li><li><a class="nounderline abstract_t">Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99:1858.</a></li><li><a class="nounderline abstract_t">Humbert M, Sanchez O, Fartoukh M, et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999; 13:1351.</a></li><li><a class="nounderline abstract_t">Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43:56S.</a></li><li><a class="nounderline abstract_t">Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999; 34:1184.</a></li><li><a class="nounderline abstract_t">Oudiz RJ, Widlitz A, Beckmann XJ, et al. Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension. Chest 2004; 126:90.</a></li><li><a class="nounderline abstract_t">Kitterman N, Poms A, Miller DP, et al. Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY®. Mayo Clin Proc 2012; 87:825.</a></li><li><a class="nounderline abstract_t">Hinojosa W, Cruz A, Cruz-Utrilla A, et al. Complications associated with peripherally inserted central catheters and Hickman™ in patients with advanced pulmonary hypertension treated with intravenous prostanoids. Respir Med 2021; 189:106649.</a></li><li><a class="nounderline abstract_t">Vachiéry JL, Hill N, Zwicke D, et al. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 2002; 121:1561.</a></li><li><a class="nounderline abstract_t">Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005; 172:1586.</a></li><li><a class="nounderline abstract_t">Wang T, Lu J, Li Q, et al. Rapid Titration of Intravenous Treprostinil to Treat Severe Pulmonary Arterial Hypertension Postpartum: A Retrospective Observational Case Series Study. Anesth Analg 2019; 129:1607.</a></li><li><a class="nounderline abstract_t">Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322.</a></li><li><a class="nounderline abstract_t">Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149:521.</a></li><li><a class="nounderline abstract_t">Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24:353.</a></li><li><a class="nounderline abstract_t">McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55:1915.</a></li><li><a class="nounderline abstract_t">Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42:158.</a></li><li><a class="nounderline abstract_t">Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136:515.</a></li><li><a class="nounderline abstract_t">Hoeper MM, Taha N, Bekjarova A, et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003; 22:330.</a></li><li><a class="nounderline abstract_t">Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 28:691.</a></li><li><a class="nounderline abstract_t">Chin KM, Rubin LJ, Channick R, et al. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. Circulation 2019; 139:2440.</a></li><li><a class="nounderline abstract_t">Frantz RP, Farber HW, Badesch DB, et al. Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry. Chest 2018; 154:126.</a></li><li><a class="nounderline abstract_t">Hoeper MM, Al-Hiti H, Benza RL, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respir Med 2021; 9:573.</a></li><li><a class="nounderline abstract_t">Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015; 34:1.</a></li><li><a class="nounderline abstract_t">Keogh AM, Mayer E, Benza RL, et al. Interventional and surgical modalities of treatment in pulmonary hypertension. J Am Coll Cardiol 2009; 54:S67.</a></li><li><a class="nounderline abstract_t">Kshettry VR, Kroshus TJ, Savik K, et al. Primary pulmonary hypertension as a risk factor for the development of obliterative bronchiolitis in lung allograft recipients. Chest 1996; 110:704.</a></li><li><a class="nounderline abstract_t">Pasque MK, Trulock EP, Kaiser LR, Cooper JD. Single-lung transplantation for pulmonary hypertension. Three-month hemodynamic follow-up. Circulation 1991; 84:2275.</a></li><li><a class="nounderline abstract_t">Schaffer JM, Singh SK, Joyce DL, et al. Transplantation for idiopathic pulmonary arterial hypertension: improvement in the lung allocation score era. Circulation 2013; 127:2503.</a></li><li><a class="nounderline abstract_t">Doyle RL, McCrory D, Channick RN, et al. Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126:63S.</a></li><li><a class="nounderline abstract_t">Yusen RD, Christie JD, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Adult Lung and Heart-Lung Transplant Report--2013; focus theme: age. J Heart Lung Transplant 2013; 32:965.</a></li><li><a class="nounderline abstract_t">Barst RJ. Role of atrial septostomy in the treatment of pulmonary vascular disease. Thorax 2000; 55:95.</a></li><li><a class="nounderline abstract_t">Reichenberger F, Pepke-Zaba J, McNeil K, et al. Atrial septostomy in the treatment of severe pulmonary arterial hypertension. Thorax 2003; 58:797.</a></li><li><a class="nounderline abstract_t">Kerstein D, Levy PS, Hsu DT, et al. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 1995; 91:2028.</a></li><li><a class="nounderline abstract_t">Nihill MR, O'Laughlin MP, Mullins CE. Effects of atrial septostomy in patients with terminal cor pulmonale due to pulmonary vascular disease. Cathet Cardiovasc Diagn 1991; 24:166.</a></li><li><a class="nounderline abstract_t">Rich S, Dodin E, McLaughlin VV. Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application. Am J Cardiol 1997; 80:369.</a></li><li><a class="nounderline abstract_t">Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 1998; 32:297.</a></li><li><a class="nounderline abstract_t">Rothman A, Sklansky MS, Lucas VW, et al. Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol 1999; 84:682.</a></li><li><a class="nounderline abstract_t">Sandoval J, Rothman A, Pulido T. Atrial septostomy for pulmonary hypertension. Clin Chest Med 2001; 22:547.</a></li><li><a class="nounderline abstract_t">Kurzyna M, Dabrowski M, Bielecki D, et al. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. Chest 2007; 131:977.</a></li><li><a class="nounderline abstract_t">Sandoval J, Gaspar J, Peña H, et al. Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension. Eur Respir J 2011; 38:1343.</a></li><li><a class="nounderline abstract_t">Esch JJ, Shah PB, Cockrill BA, et al. Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience. J Heart Lung Transplant 2013; 32:381.</a></li><li><a class="nounderline abstract_t">Khan MS, Memon MM, Amin E, et al. Use of Balloon Atrial Septostomy in Patients With Advanced Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. Chest 2019; 156:53.</a></li><li><a class="nounderline abstract_t">Yung LM, Yang P, Joshi S, et al. ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension. Sci Transl Med 2020; 12.</a></li><li><a class="nounderline abstract_t">Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2021; 384:1204.</a></li><li><a class="nounderline abstract_t">Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. Eur Respir J 2023; 61.</a></li><li><a class="nounderline abstract_t">Hoeper MM, Badesch DB, Ghofrani HA, et al. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2023; 388:1478.</a></li><li><a class="nounderline abstract_t">Souza R, Badesch DB, Ghofrani HA, et al. Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial. Eur Respir J 2023; 62.</a></li><li><a class="nounderline abstract_t">Zhang J, Kan J, Wei Y, et al. Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial. J Heart Lung Transplant 2023; 42:1140.</a></li></ol></div><div id="topicVersionRevision">Topic 8250 Version 90.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36017548" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20543192" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1682593" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15002758" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9727772" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9768734" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10080486" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30545971" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk stratification and medical therapy of pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21680644" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25837032" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Validation of two predictive models for survival in pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30772387" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31563497" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Retrospective Validation of the REVEAL 2.0 Risk Score With the Australian and New Zealand Pulmonary Hypertension Registry Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28775047" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34737226" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30545968" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Haemodynamic definitions and updated clinical classification of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1603139" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2954725" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15459304" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Treatment of pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15939821" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2182919" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Chronic cor pulmonale. Etiology and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6091508" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430735" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15464333" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6491082" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19155250" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A meta-analysis of randomized controlled trials in pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17540187" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The value of approved therapies for pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18572079" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28427554" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27482837" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Guanylate cyclase stimulators for pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26308684" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15963102" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23984728" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Macitentan and morbidity and mortality in pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26493786" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470885" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Tadalafil therapy for pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Tadalafil for the Treatment of Pulmonary Arterial Hypertension</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23883378" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Riociguat for the treatment of pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25614164" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27067479" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26699168" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Selexipag for the Treatment of Pulmonary Arterial Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29307087" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17079256" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26022952" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26113687" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22628490" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23307827" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23669822" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31765604" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25657022" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25657022" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16697324" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17164394" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Sitaxsentan for treatment of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16889636" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Critical steps in fluoroquinolones and carbapenems prescriptions: results from a prospective clinical audit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18625676" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18625676" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33765691" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Endothelin receptor antagonists for pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16053970" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Ambrisentan therapy for pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18506008" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19909879" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11597664" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11907289" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Bosentan therapy for pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15684287" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Survival with first-line bosentan in patients with primary pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12853530" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15194180" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Endothelin receptor antagonists in pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18812445" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22933513" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : An update on the use of ambrisentan in pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22933513" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : An update on the use of ambrisentan in pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23648946" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30701543" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Phosphodiesterase 5 inhibitors for pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10908271" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11183578" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Sildenafil in primary pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16291984" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Sildenafil citrate therapy for pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18187744" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21546436" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21471085" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33526303" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18552131" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18552131" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16537868" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11897647" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16899485" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18403673" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23953817" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : One-year experience with intravenous treprostinil for pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31042010" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Prostacyclin for pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8053614" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2107780" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8532025" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9247503" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9813561" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12204511" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10351941" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10357693" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10199883" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10445611" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15194179" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Prostanoid therapy for pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10520810" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249447" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22883740" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY®.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34673343" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Complications associated with peripherally inserted central catheters and Hickman™in patients with advanced pulmonary hypertension treated with intravenous prostanoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12006444" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16151039" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31743181" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Rapid Titration of Intravenous Treprostinil to Treat Severe Pulmonary Arterial Hypertension Postpartum: A Retrospective Observational Case Series Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12151469" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Inhaled iloprost for severe pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18936500" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15358690" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20430262" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12849677" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11926786" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12952269" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17012628" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30982349" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29355551" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33773120" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25085497" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19555860" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Interventional and surgical modalities of treatment in pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8797415" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Primary pulmonary hypertension as a risk factor for the development of obliterative bronchiolitis in lung allograft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1959182" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Single-lung transplantation for pulmonary hypertension. Three-month hemodynamic follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23697910" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Transplantation for idiopathic pulmonary arterial hypertension: improvement in the lung allocation score era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249495" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24054805" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Adult Lung and Heart-Lung Transplant Report--2013; focus theme: age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10639523" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Role of atrial septostomy in the treatment of pulmonary vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12947142" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Atrial septostomy in the treatment of severe pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7534664" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1722434" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Effects of atrial septostomy in patients with terminal cor pulmonale due to pulmonary vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9264443" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9708453" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10498139" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11590848" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Atrial septostomy for pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17426198" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21349914" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23415728" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30910639" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Use of Balloon Atrial Septostomy in Patients With Advanced Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32404506" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33789009" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Sotatercept for the Treatment of Pulmonary Arterial Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36041750" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36877098" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37696565" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36990173" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
